AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought ...

23, 2022. In 2014, Crews was shot in the chest in his Coppell apartment that he shared with his girlfriend Brenda Kelly. (Shafkat Anowar / Staff Photographer) Jonathan Crews was most likely killed ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. The vaccine — called Vaxzevria and ...

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Under the deal, AstraZeneca will enter ...

A Utah mother who says she was “permanently disabled” after taking part in the US clinical trial of AstraZeneca’s COVID-19 vaccine is suing the drug manufacturer because it failed to cough ...

LONDON, Nov 4 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

LONDON, Nov 12 (Reuters) - AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about ...

Guidance AstraZeneca reiterates its Total Revenue and Core EPS guidance 5 for FY 2025 at CER, based on the average foreign exchange rates through 2024.